Predicting response to hormone therapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with invasive breast cancer that is estrogen receptor-positive (more than 10% of cells) and HER2-negative or HER2-low.
- Your breast cancer is early stage (stage 1 to 3) and can be removed with surgery.
- You are able to take oral medications and are willing to follow the study schedule.
- You are 21 years old or older.
- You understand the study and can give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
This study collects small tissue samples from your breast cancer before, during, and after chemotherapy and immunotherapy to identify early signs of how well the treatment is working. The goal is to better predict treatment response and improve outcomes for patients with triple-negative or high-risk hormone-positive breast cancer.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This study looks at whether biopsy test results can help predict how well hormone therapy will work for advanced or recurrent endometrial cancer. It may help doctors choose the most effective hormonal treatment sooner.
This study looks at how a hormone-blocking medicine (endocrine therapy) given before surgery affects a marker called Ki67 in your breast cancer cells. The goal is to see if the medicine can slow the growth of the cancer, which may help doctors choose the best treatment for you.
Hear when a new Breast Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.